Our analysis showed that FAM189A2 and MYZAP were specifically downregulated in the Her2 subtype, and high FAM189A2 expression predicted high RFS in Her2-subtype breast cancer (p < 0.05), while low MYZAP expression predicted high OS in Her2-subtype breast cancer (p < 0.05). This evidence concerns the gene ERBB2 and breast cancer.